Evidence map›Paper›PMID 36102287›Full record

Trial reportHuman brain mapping2022

Early effect of thrombolysis on structural brain network organisation after anterior-circulation stroke in the randomized WAKE-UP trial.

Eckhard Schlemm, Märit Jensen, Amy Kuceyeski, Keith Jamison, Thies Ingwersen, Carola Mayer, Alina Königsberg, Florent Boutitie, Martin Ebinger, Matthias Endres and 14 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Human brain mapping, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 12 institutions in 9 countries.

Eckhard SchlemmKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-5729-2935
Märit JensenKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-7793-0941
Amy KuceyeskiDepartment of Radiology, Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0002-5050-8342
Keith JamisonDepartment of Radiology, Weill Cornell Medicine, New York, New York, USA.
Thies IngwersenKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Carola MayerKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Alina KönigsbergKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Florent BoutitieDepartment of Radiology, Weill Cornell Medicine, New York, New York, USA.
Martin EbingerCentrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, Germany.
Matthias EndresCentrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jochen B FiebachCentrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jens FiehlerDepartment of Diagnostic and Interventional Neuroradiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Ivana GalinovicCentrum für Schlaganfallforschung Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, Germany.
Robin LemmensDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.
Keith W MuirInstitute of Neuroscience & Psychology, University of Glasgow, Glasgow, UK.
Norbert NighoghossianDepartment of Stroke Medicine, Université Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA-Lyon, Lyon, France.
Salvador PedrazaDepartment of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
Josep PuigDepartment of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
Claus Z SimonsenDepartment of Neurology, Aarhus University Hospital, Aarhus, Denmark.
Vincent ThijsStroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia.
Anke WoutersDepartment of Neurology, University Hospitals Leuven, Leuven, Belgium.
Christian GerloffKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Götz ThomallaKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Bastian ChengKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0003-2434-1822
Universität Hamburg · DECharité - Universitätsmedizin Berlin · DECornell University · USInstitut d'Investigació Biomèdica de Girona · ESUniversité Claude Bernard Lyon 1 · FRAarhus University Hospital · DKAmsterdam University Medical Centers · NLGerman Center for Neurodegenerative Diseases · DEHumboldt-Universität zu Berlin · DEThe University of Melbourne · AUUniversity of Glasgow · GBVIB-KU Leuven Center for Brain & Disease Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The symptoms of acute ischemic stroke can be attributed to disruption of the brain network architecture. Systemic thrombolysis is an effective treatment that preserves structural connectivity in the first days after the event. Its effect on the evolution of global network organisation is, however, not well understood. We present a secondary analysis of 269 patients from the randomized WAKE-UP trial, comparing 127 imaging-selected patients treated with alteplase with 142 controls who received placebo. We used indirect network mapping to quantify the impact of ischemic lesions on structural brain network organisation in terms of both global parameters of segregation and integration, and local disruption of individual connections. Network damage was estimated before randomization and again 22 to 36 h after administration of either alteplase or placebo. Evolution of structural network organisation was characterised by a loss in integration and gain in segregation, and this trajectory was attenuated by the administration of alteplase. Preserved brain network organization was associated with excellent functional outcome. Furthermore, the protective effect of alteplase was spatio-topologically nonuniform, concentrating on a subnetwork of high centrality supported in the salvageable white matter surrounding the ischemic cores. This interplay between the location of the lesion, the pathophysiology of the ischemic penumbra, and the spatial embedding of the brain network explains the observed potential of thrombolysis to attenuate topological network damage early after stroke. Our findings might, in the future, lead to new brain network-informed imaging biomarkers and improved prognostication in ischemic stroke.

Indexed as

Brain IschemiaIschemic StrokeStrokeBrainFibrinolytic AgentsHumansThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeFibrinolytic AgentsTissue Plasminogen Activatorischemic strokenetwork neurosciencestructural connectivitysystemic thrombolysis

Identifiers

PMID36102287
PMCPMC9582379
OpenAlexW4295757111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.